Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of 42.9% and a stable disease rate of 21.4% based on independent assessment in the first 28 patients in the Phase II VISION trial to treat advanced non-small cell lung cancer (NSCLC) in patients harboring c-MET exon 14 skipping mutations.
Based on investigator assessment, tepotinib led to a confirmed objective response rate (ORR) of 53.6% and a stable disease rate of 17.9% in the first 28 patients. ...
BCIQ Target Profiles
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)